Received: 24 January 2022
Accepted: 24 February 2022
First Online: 21 March 2022
: The ESPOIR study was conducted with the approval of the Institutional Review Board of Montpellier University Hospital. All patients gave their signed informed consent to participate in the cohort (ClinicalTrials.gov identifier: NCT03666091). Concerning patients included in the SATRAPE study (ClinicalTrials.gov.identifier: NCT00234234), the study was approved by the regional ethics committee (CPP Nord Ouest 1, France) and all participants gave written informed consent at the time of enrolment.
: No individual person’s data are present in the manuscript. All data are completely anonymized.
: The authors declare that they have no competing interests.